Get started
Author

Sean F. Landrette

Observed names: Landrette Sean Francis, Landrette, Sean F., S F Landrette, S Landrette, S. F. Landrette, S. Landrette, Sean Francis L, Sean Francis Landrette, Sean Landrette
Observed institutions: National Institutes of Health, Howard Hughes Medical Institute, University of Massachusetts Chan Medical School, Erasmus MC, Yale University, National Human Genome Research Institute, National Cancer Institute, Arvinas (United States), LAM Therapeutics (United States), KU Leuven
ORCID: 0009-0008-0973-0591
Observed ORCID: 0009-0008-0973-0591
OpenAlex ID: A5016926162
Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma
2017 · Sophia Gayle, Sean Landrette, et al. · Blood · 203
Cbfβ-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia
2006 · Ya-Huei Kuo, Sean F. Landrette, et al. · Cancer Cell · 148
PDF
Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia
2004 · L. H. Castilla, P. Perrat, et al. · Proceedings of the National Academy of Sciences · 134
Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11
2004 · Sean F. Landrette, Ya-Huei Kuo, et al. · Blood · 130
PDF
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2024 · Lawrence B. Snyder, Taavi K. Neklesa, et al. · Molecular Cancer Therapeutics · 94
PDF
Identification of PLX 4032‐resistance mechanisms and implications for novel RAF inhibitors
2013 · Jaehyuk Choi, Sean F. Landrette, et al. · Pigment Cell & Melanoma Research · 57
PDF
Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling
2012 · John Anto Pulikkan, Dmitri Madera, et al. · Blood · 52
PDF
The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells
2011 · S F Landrette, D Madera, et al. · Leukemia · 36
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma
2013 · Thomas K. Ni, Sean F. Landrette, et al. · Proceedings of the National Academy of Sciences · 33
Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial
2024 · Suma Babu, Katharine A Nicholson, et al. · Brain · 30
piggyBac Transposon Somatic Mutagenesis with an Activated Reporter and Tracker (PB-SMART) for Genetic Screens in Mice
2011 · Sean F. Landrette, Jonathan C. Cornett, et al. · PLoS ONE · 24
PDF
B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition
2017 · Sophia Gayle, Sean Landrette, et al. · Autophagy · 21
PDF
LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML
2019 · Neil Beeharry, Sean Landrette, et al. · Blood Advances · 16
piggyBac Insertional Mutagenesis Screen Identifies a Role for Nuclear RHOA in Human ES Cell Differentiation
2015 · Sophia Gayle, Yukun Pan, et al. · Stem Cell Reports · 15
PDF
Efficient genome-wide first-generation phenotypic screening system in mice using the piggyBac transposon
2019 · Hao Chang, Yukun Pan, et al. · Proceedings of the National Academy of Sciences · 12
Characterization of Fluorescent Eye Markers for Mammalian Transgenic Studies
2011 · Jonathan C. Cornett, Sean F. Landrette, et al. · PLoS ONE · 10
PDF
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma
2024 · Paolo F. Caimi, Scott F Huntington, et al. · Blood · 9
PDF
Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.
2020 · Catherine S. Magid Diefenbach, Jonathan B Cohen, et al. · Journal of Clinical Oncology · 8
Somatic Genetics Empowers the Mouse for Modeling and Interrogating Developmental and Disease Processes
2011 · Sean F. Landrette, Tian Xu · PLoS Genetics · 7
PDF
Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader
2023 · Jessica Teh, Shannon Bessonett, et al. · Cancer Research · 6
Abstract 3075: Enhanced efficacy of ARV-471, a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models
2023 · Jessica Teh, Elizabeth Bortolon, et al. · Cancer Research · 4
Abstract 1655: ARV-393, a PROTAC B-cell lymphoma 6 (BCL6) degrader, combined with biologics or small molecule inhibitors (SMIs) induces tumor regressions in diffuse large B-cell lymphoma (DLBCL) models
2025 · Anna Van Acker, Lynn DeCarr, et al. · Cancer Research · 3
Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer
2026 · Martin Smoragiewicz, Alice Bernard-Tessier, et al. · Clinical Cancer Research · 2
Data from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
2025 · Lawrence B. Snyder, Taavi K. Neklesa, et al. · 2
LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease
2019 · Neil Beeharry, Sean Landrette, et al. · Blood · 2
Works count: 62
Citation count: 1,061
H-index: 14
I10-index: 16
Year
Topic
Type